

FOR IMMEDIATE RELEASE

Contacts:

Peter M. Columbus
Kaye Scholer LLP
Tel: 212.836.8722
pcolumbus@kayescholer.com

Vivian Hood
Jaffe Associates, Inc.
Tel: 904.220.1915
hoodv@jaffeassociates.com

COURT HOLDS PFIZER'S PATENT FOR NORVASC® VALID AND ENFORCEABLE AGAINST MYLAN

Kaye Scholer LLP Successfully Defends Pfizer's Norvasc ® Patent for Third Time

NEW YORK, Thursday, March 1, 2007 – A federal judge in the U.S. District Court for the Western District of Pennsylvania has found that Pfizer Inc.'s patent for the compound amlodipine besylate is valid, enforceable and would be infringed by Mylan Laboratories Inc.'s generic version of Pfizer's blockbuster hypertension drug Norvasc®.

On February 27, 2007, the judge enjoined Mylan from selling and marketing a generic version until the patent (U.S. Patent No. 4,879,303) expires in September 2007. Mylan had filed an Abbreviated New Drug Application (ANDA) in May 2002, indicating its intent to produce a generic copy of Norvasc ®.

Pfizer's lead trial attorneys Milton Sherman and Richard G. Greco of Kaye Scholer LLP, have successfully enforced the amlodipine besylate patent against three generic companies in the past year, all in bench trials. In January 2006, a federal judge in the U.S. District Court for the Northern District of Illinois found that generic manufacturer Apotex infringed the patent and that it is valid and enforceable. In August 2006, the U.S. District Court for the Middle District of North Carolina upheld Pfizer's patent against generic manufacturer Synthron Pharmaceuticals. Both judgments have been appealed.

Pfizer's patent enforcement action against a fourth generic company, Dr. Reddy's Laboratories Ltd., based on its ANDA for its version of Norvasc®, is pending and stayed. It has agreed to be governed by the outcome of the Mylan action.

"We are very pleased that this judge also recognized the validity and enforceability of Pfizer's patent for this popular hypertension drug," said Sherman.

About Kaye Scholer's Patent Litigation Group

Kaye Scholer was a pioneer among large general practice law firms when it began doing patent litigation in the mid-1970s with just a few litigators. Today, the Patent Litigation Group has grown to more than 60 lawyers and Ph.D. scientists. The lawyers who comprise the Patent Litigation Group combine technical training with expertise in complex civil litigation. Most have degrees in chemistry, biology and molecular biology, electrical and mechanical engineering, or computer science.

Kaye Scholer's Patent Litigation Group has handled patent infringement cases involving a wide range of technologies and products, and major patent matters in the computer, semiconductor, biotechnology, pharmaceutical, medical device, electronic, aerospace, and fiber-manufacturing industries. The group often has acted as primary counsel in worldwide patent litigation involving parallel cases for clients in many countries, as well as multi-district patent litigation in the United States. The firm also has extensive experience with major patent-antitrust litigations.

About Kaye Scholer

Kaye Scholer refers to Kaye Scholer LLP and its affiliates, with offices in New York, Chicago, Frankfurt, London, Los Angeles, Shanghai, Washington, D.C., and West Palm Beach. Founded in New York City in 1917, Kaye Scholer now includes some 525 attorneys and represents public and private companies, governmental entities, financial institutions, and other organizations in matters around the world. Additional information is available on the firm's website: www.kayescholer.com.

###